BRONCUS-B (02216) rose nearly 10%, gaining 9.96% to HK$2.65 by the time of writing, with a turnover of HK$3.2929 million. On the news front, on the evening of January 12, Broncus Medical announced that its BroncTarget® Lung Targeted Denervation Radiofrequency Ablation System (referred to as the "BroncTarget® System") has officially entered the Innovative Medical Device Special Review Program of China's National Medical Products Administration (the product name disclosed in the NMPA public document is: "Lung Radiofrequency Ablation System"). This signifies that the product's core technological originality and significant clinical value have received recognition from the national medical products authority. Currently, the confirmatory clinical trial for the BroncTarget® System is progressing in an orderly manner, with 28 hospitals across the country simultaneously advancing patient recruitment.

Furthermore, according to a disclosure on Broncus Medical's official WeChat account, its self-developed BroncAblate® Zhiheng® Lung Radiofrequency Ablation System recently obtained medical device listing (registration approval) from the Hong Kong Department of Health. This marks the official commercial launch in Hong Kong of this world's first natural orifice radiofrequency ablation interventional device for lung cancer treatment. During the same period, the FleXNeedleCN disposable endoscopic suction biopsy needle also received medical device listing (registration approval) from the Hong Kong Department of Health.

Additionally, the Tuokuo® BroncTru® single-use bronchoscopic dilation catheter successfully obtained approval from the Indonesian Ministry of Health, formally entering the Indonesian market and achieving a new breakthrough in the Southeast Asian market.